MTOR and rhabdomyosarcoma: Based on PPTP/C results, a randomized phase 2 trial was conducted for patients with relapsed rhabdomyosarcoma comparing the mTOR inhibitor temsirolimus to bevacizumab, with each agent being given with vinorelbine plus cyclophosphamide (Mascarenhas et al., 2019b).